Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7645MR)

This product GTTS-WQ7645MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7645MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ427MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ10331MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ2550MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ10576MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ9478MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ10604MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ11917MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ3630MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW